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Abstract: FIBROWALK is a multicomponent program including pain neuroscience education, thera-
peutic exercise, cognitive behavioral therapy and mindfulness training that has recently been found to
be effective in patients with fibromyalgia (FM). This RCT started before the COVID-19 pandemic and
was moved to a virtual format (i.e., online videos) when the lockdown was declared in Spain. This
study is aimed to evaluate the efficacy of a virtual FIBROWALK compared to Treatment-As-Usual
(TAU) in patients with FM during the first state of alarm in Spain. A total of 151 patients with FM
were randomized into two study arms: FIBROWALK plus TAU vs. TAU alone. The primary out-
come was functional impairment. Secondary outcomes were kinesiophobia, anxiety and depressive
symptomatology, and physical functioning. Differences between groups at post-treatment assess-
ment were analyzed using Intention-To-Treat (ITT) and completer approaches. Baseline differences
between clinical responders and non-responders were also explored. Statistically significant improve-
ments with small-to-moderate effect sizes were observed in FIBROWALK+TAU vs. TAU regarding
functional impairment and most secondary outcomes. In our study, the NNT was 5, which was,
albeit modestly, indicative of an efficacious intervention. The results of this proof-of-concept RCT
preliminarily support the efficacy of virtual FIBROWALK in patients with FM during the Spanish
COVID-19 lockdown.
Keywords: fibromyalgia; multicomponent treatment; pain neuroscience education;
therapeutic exercise; cognitive behavioral therapy; mindfulness; randomized controlled trial;
COVID-19; online treatment; teletherapy
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1. Introduction
Fibromyalgia (FM) is a chronic syndrome, of unknown etiology, characterized by
widespread musculoskeletal pain and multiple concomitant symptoms, including fatigue and
sleep disturbances, with an estimated prevalence of between 0.2 and 6.6% worldwide [1], and
of 2.45% in Spain [2].
FM frequently coexists with psychological distress, anxiety, depression and other co-
morbid conditions such as chronic fatigue syndrome [1,3,4]. Although the etiopathogenesis
of FM is still not clearly understood, a hypersensitization of the central nervous system
characterized by an unbalanced function between descending inhibitory and facilitation
pathways—which would facilitate hyperalgesia and allodynia—has been postulated [5,6].
The function of the descending nociceptive inhibitory pathway [6,7] is known to be altered
by cognitive biases—such as maladaptive thoughts—along with emotional and behavioral
factors, which, in turn, further potentiate the pain experience [8,9].
Current therapeutic strategies in FM usually combine pharmacological and non-
pharmacological approaches [10–13], and multicomponent non-pharmacological treat-
ments are currently considered the gold standard [12,14–17]. Regarding therapy compo-
nents proved to be effective in FM, Pain Neuroscience Education (PNE) [18–28] is aimed at
changing patients’ pain beliefs, emphasizing how overprotective behaviors can modulate
pain experience [29–31], and it has been found to be effective for reducing pain disability,
catastrophizing, avoidance behaviors and physical inactivity in patients with FM [32]. On
the other hand, Cognitive Behavioral Therapy (CBT) and therapeutic exercise are also core
pillars of intervention in FM [33–35], and combining both has been seen to be particularly
effective at treating several FM symptoms [36–38] (e.g., relieving pain, fatigue, depression,
and improving psychological well-being and physical functioning [12,33]). Furthermore,
mindfulness training [39] has also been found to be an efficacious and cost-effective treat-
ment for improving functional impairment, anxiety, depression, and quality of life in
patients with FM [13,37]. The FIBROWALK program is an evidence-based multicomponent
strategy based on the combination of the aforementioned therapeutic components with
positive results in two recent RCTs in FM [40,41].
The outbreak of the coronavirus SARS-CoV-2 pandemic, associated mobility restric-
tions and the overloading of hospital services drastically changed the therapeutic paradigm
in healthcare worldwide, with most non-urgent face-to-face therapies being canceled or
postponed and replaced by telematic and virtual therapies. Patients with FM, similar to
others with chronic medical conditions, were profoundly affected by these restrictions. In
this regard, many studies indicate that the delay or the discontinuation of treatments in
patients with chronic pain results in a deterioration of symptoms, a perception of pain
aggravation and worsened quality of life [42–44].
The FIBROWALK program has proved to be an effective treatment for FM patients but,
up to now, was only validated in hospital [41] and outdoor settings [40]. Given the need
for moving effective treatments to the emerging field of telemedicine to continue providing
support to patients with FM during the COVID-19 lockdown, the FIBROWALK program
was adapted into a home-based virtual-format therapy. This adaptation was in line with the
opinion of different international chronic pain expert panels at the beginning of pandemics
(e.g., [45,46]), who prompted to rapidly implement telehealth support for patients with
chronic pain to limit the impact of the pandemic on this particularly vulnerable population.
Similar virtual approaches (e.g., using videos) have also been used by other health centers
in Spain in the search of the benefit of patients with FM under quarantine. In this regard,
Hernando-Garijo and colleagues [47] made available a home-based intervention of aerobic
exercise during lockdown, finding, in a small sample size, RCT- positive results in pain
intensity, functional impairment, pain catastrophizing and emotional distress compared
to a passive control group. To date, as far as we know, no study has evaluated the
efficacy of a virtual multicomponent treatment for FM in general or during the pandemic
outbreak specifically.
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Taking this state of the question as its foundation, this proof-of-concept RCT was aimed
at making a preliminary assessment of the efficacy of the FIBROWALK multicomponent
treatment, moved to a virtual format, as an add-on to Treatment-As-Usual (TAU). The ef-
ficacy was evaluated on functional impairment (as main outcome) and other secondary
outcomes, such as kinesiophobia, anxiety and depression symptoms, and physical function-
ing. Specifically, we expected statistically significant and clinically relevant improvement in
functional impairment and other secondary outcomes for FIBROWALK+TAU vs. TAU alone
after treatment. Baseline differences between FIBROWALK responders vs. non-responders
were explored to delimit potential patient characteristics related to the efficacy of the program,
and the Number-Need-to-Treat (NNT) was calculated.
2. Materials and Methods
2.1. Design
A single-blind Randomized Controlled Trial (RCT) was conducted. Data were collected
at baseline and at the end of the 12-week intervention. All procedures were conducted
in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki
and subsequent updates. The FIBROWALK study protocol was approved by the Ethical
Committee of Clinical Investigation of Vall d’Hebron Hospital (code: PR(AG)249/2020) and
was registered at ClinicalTrials.gov NCT04284566. This study is reported according to the
guidelines issued by the Consolidated Standards of Reporting Trials (CONSORT) [48].
2.2. Participants
A total of 151 participants diagnosed with FM, who met the selection criteria, and
at the same time had been visited by the physical therapist from the Central Sensitivity
Syndromes Specialized Unit (CSSSU) at the UHVH, were recruited from November 2019
to March 2020 to participate in this study. The treatment program was delivered from
March 2020 to June 2020. The state of alarm was declared by the Spanish government on
14 March 2020 and lasted until 10 May 2020. This exceptional measure confined Spaniards
in their homes. Inclusion criteria for the participants were: (a) FM diagnosis according
to the 2010/2011 American College of Rheumatology (ACR) criteria, (b) ≥18 years old,
(c) able to understand Spanish, and (d) able to provide written informed consent. Exclusion
criteria were having terminal illnesses or programmed treatments that might interrupt the
participation in the study.
2.3. Procedure
Participants were firstly recruited through an initial screening interview performed
by the main researcher (MS), who provided an overview of the study. Informed written
consent was obtained from all participants before the baseline examination. Participants
were informed of their right to withdraw from the study at any time, with the guarantee
that, if they desired, they could continue receiving their usual treatment. After completing
baseline examinations, individuals who agreed to participate in the study were assigned
to an alphanumeric code list and were randomized using the SPSS statistical package
(v25) (Kaysville, UT, USA) to either the active group or control group (TAU). This process
was carried out using numbered envelopes containing sheets with information regarding
participant allocation. The envelopes were prepared by a nurse from the CSSSU. Neither
the participants nor the clinical professional who conducted the program (MS) could
be blinded. However, MS did not participate in any stage of the patient assessment
process, and the researcher responsible for the outcome measures (MM) was blinded to
the treatment allocation. All patients were evaluated before (baseline) and after (post) the
12-week treatment.
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2.4. Treatment Arms
Participants allocated to the FIBROWALK arm underwent a multicomponent strategy
based on therapeutic exercise, pain neuroscience education, CBT and mindfulness training.
After the first face-to-face session, the FIBROWALK program was moved to a virtual format
due to the proclamation of the Spanish state of alarm. From then on, a link to a 60 min video
(hosted on a private YouTube channel) was sent by email once a week for the following
11 weeks (total time of the FIBROWALK program: 12 weeks). Each video sent provided
detailed guidelines explaining how to perform different home-based aerobic exercises
(such as walking down the hallway at home); education in the neuroscience of pain (based
on the book “Explain Pain” by David Butler, Lorimer Moseley and Arte Sunyata and
the educational recommendations of the Pain in Motion team led by Jo Nijs); and CBT
based on the analysis of basic psychological processes and aimed at decreasing anxiety
and depressive symptoms, at reducing pain catastrophizing and at changing inadequate
emotional regulation strategies. For greater detail on the FIBROWALK contents, see the
study by Serrat et al. [41]. A brief questionnaire (with 5 to 10 items) aimed at verifying if
participants were actually involved in FIBROWALK virtual treatment was sent by email
every week. These brief questionnaires asked for actual participants’ adherence to the
proposed homework exercises (i.e., mindfulness practice, breathing exercises, relaxation
training, therapeutic physical training) and also allowed us to check if FIBROWALK videos
were watched or not. For the latter point, very basic concepts precisely explained in each
video were checked (e.g., “Please, provide a short example of a catastrophic thought”) to
ensure that particular video was watched. These weekly checks were used for the early
detection of potential adherence problems (e.g., not watching the videos, not doing the
exercises) as well as potential dropouts. The therapist (MS) contacted (via SMS and/or
telephone calls) patients who did not answer the questionnaire or reported any issue
related to the program or the study (e.g., not being able to do the homework, watch the
videos, answer the questionnaire, etc.) and provided solutions for enhancing adherence.
If needed, patients unable to watch or respond to the questionnaire in a specific week
could ask for an extension date (e.g., watching/responding in a 2–3-week timeframe).
Participants could also contact the therapist (via email) at any time if any other problem
related to the treatment or the study arose.
The treatment as usual (TAU) provided to the control group patients of this study
was mainly based on the administration of drugs adjusted to the symptomatic profile of
each patient (amitriptyline, duloxetine, pregabalin and/or tramadol at low doses), with
complementary advice on aerobic exercise adapted to the patients’ physical abilities and basic
health education on their pathology. Patients in the control group remained on a waiting list
so that at the end of the RCT they could benefit from the FIBROWALK treatment.
The prescribed drugs were not modified in any participant during the twelve weeks
of the study. The use of rescue 1 g paracetamol tablets (maximum 1 tablet/8 h) was only
allowed in the case of acute worsening of symptoms.
2.5. Study Measures
2.5.1. Socio-Demographic and Clinical Characteristics
An ad hoc questionnaire gathering socio-demographic and clinical information was used
to collect the following patient data: age, gender, educational level, employment situation,
living arrangement (alone/accompanied), civil status, body mass index, illness self-perceived
start/duration (in years), incapacity certificate obtained (indicating level of incapacity) or
requested, and chronic fatigue syndrome diagnosis (issued by a rheumatologist).
2.5.2. Primary Outcome
The Revised Fibromyalgia Impact Questionnaire (FIQR) [49] was used to measure
participants’ functional impairment related to FM during the last week. It consists of
21 items answered on a 0–10 numerical scale and is divided into three dimensions: physical
dysfunction (score ranges from 0 to 30), overall impact (score ranges from 0 to 20), and
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intensity of symptoms (scores from 0 to 50), with higher scores indicating greater func-
tional impairment of FM. The FIQR might be considered the gold standard instrument
for assessing multidimensional function/health-related quality of life (FIQR total score)
and has been used in several RCTs as a main outcome for assessing the clinical impact of
non-pharmacological interventions (e.g., 13, 40, 41). The Spanish version shows excellent
internal consistency (Cronbach’s α = 0.91) [50]; in our sample, the α was 0.94.
2.5.3. Secondary Outcomes
The Tampa Scale for Kinesiophobia (TSK) [51] was used to measure kinesiophobia.
This scale has 11 items, which can be answered with a 4-point Likert scale (ranges from 0 to
11). Total scores of the TSK can go from 11 to 44 points, with higher scores indicating greater
pain and fear of movement. The Spanish version shows adequate internal consistency
(α = 0.79) [52]; in our sample, α = 0.90.
Depressive and anxiety symptomatology were measured with the Hospital Anxiety and
Depression Scale (HADS) [53], which is divided into two dimensions (HADS-Anxiety and
HADS-Depression), each dimension being further divided into 7 items, with a 4-point Likert
scale response format. HADS-A and HADS-D total scores range from 0 to 21, with higher
scores indicating higher symptom severity. The Spanish version shows adequate internal
consistency for anxiety (α = 0.87) and for depression (α = 0.87) [54]; in our sample, α = 0.89.
The physical functioning component of the 36-Item Short Form Survey (SF-PF) [55]
was used to measure physical functioning. This subscale comprises a total of 10 items, with
a 3-point Likert scale response format. Total scores are transformed in order to range from
0 to 100, with higher scores indicating better physical functioning. The Spanish version
shows adequate internal consistency (α = 0.94) [56]; in our sample, α = 0.86.
2.6. Statistical Analyses
Descriptive statistics were calculated for all variables and presented as means and
standard deviations if continuous data were used, or absolute numbers and percentages
(%) if categorical data were used. The Levene test was used to assess the equality of
variances of continuous variables and Kolmogorov–Smirnov to test sample normality and
distribution. Additionally, Student’s t-tests and χ2-tests were used to examine any possible
baseline difference between FIBROWALK and the TAU group regarding sociodemographic
and clinical characteristics.
We used analyses of covariance (ANCOVAs), including baseline values as a covariate,
to examine differences between FIBROWALK+TAU vs. TAU alone at post-treatment in the
FIQR scores and in each of the secondary outcomes. ANCOVA has been shown to have
greater power to detect change than analysis of variance (ANOVA) in randomized study
designs [57]. All outcomes were analyzed using the last observation carried forward (LOCF)
method for imputing missing values in an Intention-To-Treat (ITT) approach. A sensitivity
analysis was also conducted using the completer sample (i.e., completer approach). We
also calculated the effect size (Cohen’s d) for each pairwise comparison, using the pooled
baseline SD to measure the differences in the baseline–post mean values and to correct
them for the population estimate [58]. The usual rule of thumb of d = 0.20, small; 0.50,
moderate; and 0.80, large was used for interpreting observed effect sizes. In order to reduce
the false discovery rate associated with multiple comparisons, we applied the Benjamini–
Hochberg correction, which generates local significance levels where the first statistical
test (the smallest p-value in ordered sequence) is assigned as the local significance level,
which corresponds to the Bonferroni correction [59]. In addition, to assess the clinical
significance of the improvement on the primary outcome (i.e., FIQR scores), we classified
participants into two categories (i.e., responders vs. non-responders) according to their
baseline-to-post change, using the criteria of ≥20% reduction in the pre–post FIQR total
score [49]. This classification was then used to calculate the number needed to treat (NNT)
in FIBROWALK+TAU compared to TAU. The NNT is an index aimed at helping clinicians
to make results from RCTs more meaningful to them, and it refers to the estimated number
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of patients who need to be treated with a novel proposed treatment (here, FIBROWALK)
for one additional patient to benefit (i.e., vs. the control arm). An NNT between 2 and 5 is
considered to be indicative of a clinically effective treatment in pharmaceutical research [60].
A 95% CI for the NNT was also computed. T-tests and χ2-tests were also conducted to
evaluate baseline differences between completers vs. non-completers (both groups), and
between responders vs. non responders within the FIBROWALK+TAU arm.
All data analyses of the present study were performed using the SPSS v25 statistical
software package.
3. Results
3.1. Participants’ Flow and Treatment Adherence
Of the 177 potential eligible participants, 26 were excluded at the screening for not
meeting the selection criteria (i.e., not providing written informed consent). The initial
study sample, consisting of 151 patients, was then randomized into the two study arms,
with 75 and 76 individuals per arm (see Figure 1). All participants in the FIBROWALK+TAU
group attended the 12 sessions of the program. The participants’ mean age was 54.35 years
old (SD = 8.68; range: 22–76), the mean body mass index was indicative of overweight
(M = 27.11, SD = 5.30), and the reported time since FM diagnosis was 15.75 years (SD = 9.16;
range: 1–52). In the total sample, 20.5% of the patients were employed, 64.2% reported
having a secondary education level or higher, and 90.1% also had a comorbid chronic
fatigue syndrome diagnosis (more details in Table 1). Statistical differences between groups
were found regarding the retention rate at post-treatment (FIBROWALK+TAU: 61.3%; TAU:
93.4%; χ2 = 22.27, p < 0.001). Non-completers from the FIBROWALK+TAU arm showed
higher FIQR baseline scores than completers did (t = 2.047; p = 0.044). Non-completers from
the TAU group showed a larger degree of incapacity than completers (χ2 = 9.78, p = 0.02)
and lower anxiety levels than completers at baseline (t = −3.131; p = 0.007).




Figure 1. CONSORT Flow diagram of participants in the randomized controlled trial. 
Table 1. Demographic and baseline clinical characteristics by treatment group. 
 FIBROWALK+TAU (n = 75) TAU (n = 76) t/χ² p 
Age (years), M ± SD 54.89 ± 8.94 53.82 ± 8.45 −0.761 0.448 
Women, n (%) 71 (94.70) 70 (92.10) 0.400 0.745 
Civil Status, n (%)   8.199 0.042 
Single 13 (17.30) 15 (19.70)   
Married 39 (52.00) 52 (68.40)   
Divorced 19 (25.30) 7 (9.20)   
Widow 4 (5.30) 2 (2.60)   
Not living Alone, n (%) 65 (86.70) 65 (85.50) 0.041 0.840 
Educational Level, n (%)   2.152 0.828 
Without Studies 2 (2.70) 2 (2.60)   
Primary Education not completed 5 (6.70) 4 (5.30)   
Primary Education 17 (22.70) 23 (30.30)   
Secondary Education 32 (42.70) 29 (38.20)   
Higher Education 18 (24.00) 18 (23.70)   
Other 1 (1.30) 0 (0.00)   
Employment Situation, n (%)   11.249 0.128 
Housekeeper 3 (4.00) 8 (10.50)   
Active 16 (21.30) 15 (19.70)   
 
Assessed for eligibility (n= 177) 
Excluded (n= 26) 
♦   Not meeting inclusion criteria (n= 26) 
Analysed (n= 76) 
♦ Excluded from ITT analyses (n= 0) 
Lost to follow-up (n= 5) 
♦ Not being able to complete the study given 
personal/familiar circumstances (n= 5) 
Allocated to intervention (n= 76) 
♦ Received allocated intervention (n= 76) 
Lost to follow-up (n= 34) 
♦ Not being able to complete the study given 
personal/familiar circumstances (n= 34) 
Allocated to intervention (n= 75) 
♦ Received allocated intervention (n= 75) 
Analysed (n= 75) 




Randomized (n= 151) 
Enrollment 
Figure 1. CONSORT Flow diagram of participants in the randomized controlled trial.
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Table 1. Demographic and baseline clinical characteristics by treatment group.
FIBROWALK+TAU (n = 75) TAU (n = 76) t/χ2 p
Age (years), M ± SD 54.89 ± 8.94 53.82 ± 8.45 −0.761 0.448
Women, n (%) 71 (94.70) 70 (92.10) 0.400 0.745
Civil Status, n (%) 8.199 0.042
Single 13 (17.30) 15 (19.70)
Married 39 (52.00) 52 (68.40)
Divorced 19 (25.30) 7 (9.20)
Widow 4 (5.30) 2 (2.60)
Not living Alone, n (%) 65 (86.70) 65 (85.50) 0.041 0.840
Educational Level, n (%) 2.152 0.828
Without Studies 2 (2.70) 2 (2.60)
Primary Education not completed 5 (6.70) 4 (5.30)
Primary Education 17 (22.70) 23 (30.30)
Secondary Education 32 (42.70) 29 (38.20)
Higher Education 18 (24.00) 18 (23.70)
Other 1 (1.30) 0 (0.00)
Employment Situation, n (%) 11.249 0.128
Housekeeper 3 (4.00) 8 (10.50)
Active 16 (21.30) 15 (19.70)
On leave 12 (16.00) 15 (19.70)
Unemployed with allowance 6 (8.00) 10 (32.20)
Unemployed without allowance 8 (10.70) 1 (1.30)
Retired 8 (10.70) 12 (15.80)
Temporary work disability 8 (10.70) 6 (7.90)
Other 14 (18.70) 9 (11.80)
Incapacity certificate, n (%) 0.221 0.896
No 23 (30.70) 26 (34.20)
Between 33% and 66% 47 (62.70) 45 (59.20)
More than 66% 5 (6.70) 5 (6.60)
With incapacity certificate
requested, n (%) 24 (32) 30 (39.5) 0.918 0.397
BMI, M ± SD 27.39 ± 5.72 26.84 ± 4.89 −0.637 0.525
ISPS, years, M ± SD 16.97 ± 9.50 14.54 ± 8.71 −1.641 0.103
With CFS, n (%) 66 (88.00) 70 (92.10) 0.711 0.429
FIQR, M ± SD 71.83 ± 15.52 72.42 ± 15.93 0.230 0.818
TSK, M ± SD 27.93 ± 8.09 28.68 ± 8.10 0.570 0.569
HADS Anxiety, M ± SD 12.49 ± 5.00 12.71 ± 4.20 0.289 0.773
HADS Depression, M ± SD 11.80 ± 5.44 12.04 ± 4.65 0.291 0.771
SF-PF, M ± SD 27.00 ± 17.01 31.18 ± 19.32 1.412 0.160
Note: Statistically significant effects appear in bold (p ≤ 0.05). BMI: Body Mass Index; CFS: Chronic Fatigue Syndrome; FIQR: Revised
Fibromyalgia Impact Questionnaire; HADS: Hospital Anxiety and Depression Scale; ISPS: Illness Self-Perceived Start; SF-PF: Physical
Functioning component of the 36-Item Short Form Survey; TSK: Tampa Scale for Kinesiophobia.
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3.2. Baseline Differences between FIBROWALK+TAU and TAU Arms
As shown in Table 1, there were no statistically significant differences between groups
in terms of demographic (except for civil status; p = 0.04) or baseline clinical characteristics.
3.3. Between-Group Differences in the Primary and Secondary Outcomes
All outcomes were analyzed following an ITT approach. Means and SD at baseline
and post-test assessments (with imputed values) in both control and intervention groups
are shown in Table 2. Significant treatment effects (p < 0.05) were found for functional
impairment, anxiety, depressive symptoms and physical functioning (with effect sizes
ranging between 0.23 and 0.48). A more robust treatment effect was found in the completer
approach (Supplementary Table S1) where significant improvements were found for all
outcomes (with d ranging from 0.33 and 0.89).
Table 2. Descriptive statistics and between-group analyses for primary and secondary outcomes from an ITT approach
(with imputation of missing data).
FIBROWALK+TAU (n = 75) TAU (n = 76) F p d
Baseline Post Baseline Post
Primary Outcome, M ± SD
FIQR 71.83 ± 15.52 66.31 ± 19.48 72.42 ± 15.93 72.66 ± 17.62 6.039 0.015 0.364
Secondary Outcomes, M ± SD
TSK 27.93 ± 8.09 25.50 ± 11.69 28.68 ± 8.10 28.66 ± 7.46 3.841 0.052 0.296
HADS Anxiety 12.49 ± 5.00 11.75 ± 5.05 12.71 ± 4.20 13.04 ± 4.57 5.225 0.024 0.231
HADS Depression 11.80 ± 5.43 10.53 ± 5.82 12.04 ± 4.65 12.17 ± 4.85 6.483 0.012 0.276
SF-PF 27.16 ± 17.06 38.72 ± 22.91 31.18 ± 19.32 33.95 ± 19.55 9.349 0.003 0.480
Note: Statistically significant effects are shown in bold (p ≤ 0.05). When the Benjamini–Hochberg correction was applied to correct for
multiple comparisons, all significant effects remained significant. FIQR: Revised Fibromyalgia Impact Questionnaire; HADS: Hospital
Anxiety and Depression Scale; ISPS: Illness Self-Perceived Start; SF-PF: Physical Functioning component of the 36-Item Short Form Survey;
TSK: Tampa Scale for Kinesiophobia.
3.4. Baseline Differences between Responders and Non-Responders within the FIBROWALK+TAU Arm
As shown in Table 3, there were not significant differences between groups in terms
of sociodemographic characteristics. However, there was a statistical difference in the
physical functioning component of the SF-PF (p = 0.036), with non-responders presenting
lower scores.





(n = 14) t/χ
2 p
Age (years), M ± SD 54.63 ± 9.69 56.64 ± 8.33 −0.718 0.479
Women, n (%) 28 (87.50) 14 (100.00) 1.917 0.166
Civil Status, n (%) 6.783 0.079
Single 5 (15.60) 0 (0.00)
Married 15 (46.90) 12 (85.70)
Divorced 9 (28.10) 2 (14.30)
Widow 3 (9.40) 0 (0.00)
Not living Alone, n (%) 29 (90.60) 13 (92.90) 0.061 0.805
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2 p
Educational Level, n (%) 2.864 0.721
Without Studies 1 (3.10) 0 (0.00)
Primary Education not completed 1 (3.10) 2 (14.30)
Primary Education 4 (12.50) 2 (14.30)
Secondary Education 16 (50.00) 6 (42.90)
Higher Education 9 (28.10) 4 (28.60)
Other 1 (3.10) 0 (0.00)
Employment Situation, n (%) 6.168 0.520
Housekeeper 0 (0.00) 2 (14.30)
Active 9 (28.10) 3 (21.40)
On leave 4 (12.50) 2 (14.30)
Unemployed with allowance 1 (3.10) 1 (7.10)
Unemployed without allowance 3 (9.40) 2 (14.30)
Retired 4 (12.50) 1 (7.10)
Temporary work disability 3 (9.40) 1 (7.10)
Other 8 (25.00) 2 (4.30)
Incapacity certificate, n (%) 3.753 0.153
No 10 (31.30) 8 (57.10)
Between 33% and 66% 18 (56.30) 6 (42.90)
More than 66% 4 (12.50) 0 (0.00)
With incapacity certificate
requested, n (%) 10 (31.30) 3 (21.40) 0.463 0.496
BMI, M ± SD 27.35 ± 5.66 25.59 ± 5.25 1.021 0.316
ISPS, years, M ± SD 14.69± 7.39 18.64 ± 12.41 −1.346 0.185
With CFS, n (%) 29 (90.60) 11 (78.60) 1.248 0.350
FIQR, M ± SD 70.74 ± 16.40 64.94 ± 14.59 1.139 0.261
SF-PF, M ± SD 25.78 ± 16.61 36.43 ± 11.84 −2.164 0.036
TSK, M ± SD 28.09 ± 7.91 28.00 ± 7.52 0.038 0.970
HADS Anxiety, M ± SD 13.19 ± 4.95 11.43 ± 4.70 1.125 0.267
HADS Depression, M ± SD 12.09 ± 5.29 10.07 ± 4.83 1.224 0.227
Note: Statistically significant effects appear in bold (p ≤ 0.05). BMI: Body Mass Index; CFS: Chronic Fatigue
Syndrome; FIQR: Revised Fibromyalgia Impact Questionnaire; HADS: Hospital Anxiety and Depression Scale;
ISPS: Illness Self-Perceived Start; SF-PF: Physical Functioning component of the 36-Item Short Form Survey; TSK:
Tampa Scale for Kinesiophobia.
3.5. Number Needed to Treat (NNT)
Fourteen patients in the FIBROWALK+TAU group (30.43%; 14 out of 46) reached the
status of responder at post-treatment (i.e., showed a decrease in their FIQR total score by at
least 20% in comparison with their baseline assessment), whilst only seven patients in the
TAU condition achieved this status (9.86%; 7 out of 71). The absolute risk reduction (ARR)
in the FIBROWALK+TAU group in comparison with TAU was 20.58% (95% CI = 5.58 to
35.57%), with an NNT = 5 (95% CI = 2.8 to 17.9), meaning that five patients would need
to be treated with FIBROWALK+TAU instead of TAU alone for one of them to become
a responder.
4. Discussion
This RCT was aimed to preliminarily evaluate the efficacy of a virtual version of the FI-
BROWALK multicomponent program compared to Treatment-As-Usual (TAU) in patients
with FM during the COVID-19 lockdown in Spain. As far as we know, it was the first study
to evaluate the short-term efficacy of a virtual multicomponent treatment for the man-
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agement of FM. The virtual FIBROWALK program arose as a necessity to provide health
support for patients with FM when the COVID-19 pandemic broke out, and comprised
weekly videos on PNE, home-based therapeutic exercise, CBT and mindfulness training.
4.1. Preliminary Efficacy of the Virtual FIBROWALK
The results of the present RCT show that the FIBROWALK intervention was efficacious
(with small-to-moderate effect sizes) in reducing impairment, depression and anxiety
symptoms and in improving physical functioning compared to TAU. Our results are
consistent with previous research on the efficacy of online treatments for FM [61–63] and
extend the already reported positive effects of FIBROWALK conducted in hospital [41] and
outdoor [40] settings to virtual environments. It is worth noting that benefits associated
with FIBROWALK administered in a virtual format were observed despite the extreme
social circumstances happening when the RCT was carried out. Such circumstances were
characterized by heavy restrictions of movement, fear, and tragically common traumatic
events related to COVID infections and, especially, to the death of friends, relatives and
acquittances. All these contingencies had a profound effect on the overall health of the
population as a whole (e.g., [63–67]) and, particularly, among people with long-term
conditions such as chronic pain and FM (e.g., [43,44,68]).
4.2. Components of the FIBROWALK
Multicomponent treatments involving physical exercise and cognitive behavioral
strategies have shown to be some of the most effective approaches at improving physical
function, psychological well-being and mental health status in patients with FM; and
they are increasingly being recommended for evidence-based clinical guidelines [14,17].
Regarding therapeutic exercise, recent meta-analyses have supported its effectiveness for
improving a wide range of FM symptoms, including pain and depressive symptomatology,
and for increasing well-being and health-related quality of life [33]. Home-based aerobic
conditioning has also been found to induce physiological and psychological benefits
in patients with FM, including improvements in pain [69]. Relatedly, in a recent small
(i.e., 17 individuals per arm) clinical trial conducted in Spanish patients with FM also during
the COVID-19 lockdown [47], an intensive 15-week (2 sessions/week) telerehabilitation
program based on aerobic exercise showed positive effects on pain intensity, functional
impairment and psychological distress compared to a passive control group. On the other
hand, CBT has been proven to be also efficacious (with small-to-medium effect sizes)
for improving pain, health-related quality of life, negative mood, disability and fatigue
in patients with FM [34,35]. In this regard, CBT is also strongly recommended by FM
clinical guidelines and even advocated as the first step of stepwise treatment approaches
for FM [17]. So, both exercise and CBT components may explain part of the therapeutic
effects observed after virtual FIBROWALK completion.
Beyond therapeutic exercise and CBT, an important strength of the FIBROWALK
protocol is the addition of PNE and mindfulness training, which constitute, respectively, a
significant change of perspective regarding the classical pain education and the CBT focus
on changing problematic thoughts. In this regard, PNE is aimed at educating patients on
the mechanisms behind chronic pain, highlighting that any credible evidence of danger
or safety in body tissues can increase or decrease pain perception, respectively [22], and
has been found to be effective in patients with FM [18–28]. It is noteworthy that PNE
seems even more effective when it is combined with therapeutic exercise, gradual exposure
techniques, and CBT [24,70], all of which are integrated elements in the FIBROWALK
program. On the other hand, mindfulness training is aimed at modifying the relationship
with one’s thoughts—to be more nonjudgmentally open to them, with acceptance—rather
than at changing their content [71]. It is also worth noting that mindfulness training was
introduced in the late 1970s in hospitals as a program (i.e., Mindfulness-Based Stress Reduc-
tion) for helping people with problems in stress management and chronic health conditions
(including chronic pain) to find alternative and more healthy ways of relating with per-
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sonal life challenges [71]. Since then, several studies have reported that mindfulness may
be an effective approach for promoting better mental health and fostering wellbeing in
heterogeneous clinical and non-clinical populations (e.g., [72–74]). Furthermore, there is
growing evidence that mindfulness can be also effective for improving core symptoms
of FM. [37,75]. The role of mindfulness on wellbeing and mental health has also been
studied during the COVID-19 pandemic. In this regard, some studies pointed out that
mindfulness, as a trait, would be related with more effective coping during lockdown [76],
and, as online intervention, it would be associated with improved wellbeing, stress and
anxiety in various samples [77,78].
4.3. The Flourishing of Teletherapy during Pandemic and beyond
Virtual treatment programs such as FIBROWALK might be promising alternatives
to conventional treatments in times of pandemic and beyond when it comes to specific
logistic barriers, such as timing, travel or access difficulties in rural areas, or wellbeing
barriers, such as patients’ fatigue, among others. They can also help in decongesting health
system services, which are overstretched worldwide as a result of the COVID-19 pandemic.
Furthermore, regarding cost-effectiveness, virtual treatments may also be highly advan-
tageous to exhausted national health systems as they may help in considerably reducing
healthcare personnel costs [79]. The implications of effective teletherapy approaches for
FM are thorough, particularly in terms of increasing the availability of specific evidence-
based treatments for FM. For instance, since healthcare professional time per patient is
limited, having an effective self-administered online program available would imply that
a professional could substantially increase the number of patients being treated without
affecting the quality of the therapy delivered or that a professional could maintain the
number of attended patients but increase the appointment time.
The COVID-19 pandemic has enforced the need for new approaches to treatment.
The positive results of this proof-of-concept RCT on the virtual FIBROWALK program
contribute to pave the way for a change in the paradigm of treatment in FM, potentially
helping to overcome barriers for delivering effective treatments before, during and beyond
the pandemic. Further RCTs evaluating the long-term effects of fully virtual FIBROWALK
out of lockdown are also warranted.
4.4. Limitations
Several limitations to this study need to be acknowledged. As a proof-of-concept RCT,
it did not have an active control group or a long follow-up period. Given that this virtual
modality of FIBROWALK had never been tested before, we preferred an experimental
design, treating this cohort of patients as a test sample. Promising clinical effects have been
achieved in this study that warrant a further study with a more robust clinical design (larger
sample size, including an active control group, with a long-term follow-up). In addition, it is
important to highlight that this clinical trial was carried out in a specialized unit of tertiary
referral hospital in the context of clinical practice. Related to the latter, strict selection
criteria could not be established due to pressures in daily clinical practice (i.e., most
patients were admitted), and, specifically, patients that requested the incapacity certificate
were also included in this RCT. Additionally, for ethical reasons, a follow-up assessment
for the TAU group was not feasible under lockdown circumstances and, accordingly, a
pre-post design was used. Long-term follow-up assessments are essential for evaluating the
effectiveness of multicomponent treatments in the context of real-world clinical practices
and should be evaluated in further RCTs including the virtual FIBROWALK program.
Moreover, as a result of treatment characteristics, participants were not blinded. Future
studies should also include a second active arm (e.g., pain education with therapeutic
exercise) for controlling treatment dosage. Although all patients allocated to FIBROWALK
were asked to respond to a brief questionnaire each week about each sessions’ contents,
there is also no complete certainty that patients had seen all the videos. Additionally, we
could not gather information about participants’ personal losses throughout the RCT, which
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we know probably happened, as a higher number of deaths were observed worldwide
(and particularly in Spain) at that time of the pandemic; this probably affected the results.
Furthermore, patients included in the study presented high impact and duration of disease
inasmuch as they were recruited from a specialized unit of a tertiary referral hospital, so
the sample cannot be representative of all the population with FM. Further research of this
treatment in primary care settings as well as in non-pandemic contexts might contribute to
addressing these challenges. The online adaptation of the program was carried out as a
result of the unexpected situation caused by the COVID-19 outbreak; this sudden program
format adaptation—along with the variable IT knowledge of participants—may have
contributed to increasing the dropout rate, which was higher than in previous RCTs using
face-to-face FIBROWALK (38.7% vs. 23% [41]). However, it is also known that attrition rates
are highly variable (4% to 54%) in online interventions for patients with chronic pain [80],
so our results fell within the expected range. Recommendations on assessment domains in
FM are mainly based on self-reported measures (e.g., core domain set for fibromyalgia in
Outcome Measures in Rheumatology Clinical Trials (OMERACT; [81]). Notwithstanding
this, further studies assessing the effects of virtual FIBROWALK should also include
complementary objective outcomes such as aerobic fitness and other measures assessed by
the clinician. Limitations in design (e.g., not having an active control group, not having
complementary objective functional measures) along with the relatively high attrition may
have caused an impact on the results of this proof-of-concept trial. In this regard, studies
with more robust study designs are needed. Further RCTs aimed at evaluating the effects
of a fully virtual version of FIBROWALK will also evaluate levels of attrition and explore
potential ways for increasing treatment adherence.
5. Conclusions
This is the first study to demonstrate the short-term efficacy of a virtual multicompo-
nent treatment compared to usual care for the management of FM during the COVID-19
lockdown in Spain. This proof-of-concept RCT preliminarily supports the efficacy of a
novel and highly accessible virtual FIBROWALK program in the approach to FM to be
used during times of the COVID-19 pandemic and beyond. Further RCTs including active
control groups with an equivalent treatment dosage and assessing the long-term efficacy of
the virtual FIBROWALK are warranted.
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